MBC Pharma, Osteros Biomedica deal

Newco Osteros debuted and announced that in early September it received exclusive, worldwide rights to develop and commercialize MBC-11 from MBC Pharma. The conjugate of cytarabine and a bisphosphonate is in preclinical development to treat cancer-induced bone disease, with Phase I testing slated to start late next year. Osteros did not disclose details. ...